Managing poor performance non-cell lung cancer patients

Annals of Oncology

Volumn 12, Issue 12, 2001, Pages 1659-1661

  Rosell, R ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIS; CARBOPLATIN; CIGARETTE SMOKE; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; GASTRIN RELEASING PEPTIDE; GEMCITABINE; HORMONE RECEPTOR; IFOSFAMIDE; MITOMYCIN; NAVELBINE; PACLITAXEL; VINDESINE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER COMBINATION CHEMOTHERAPY; CANCER MODEL; CANCER PATIENT; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CARCINOGENICITY; DAILY LIFE ACTIVITY; DRUG POTENCY; DRUG RESPONSE; EDITORIAL; FEMALE; GENE MUTATION; HUMAN; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MALE; MOUSE; NONHUMAN; ONCOGENE K RAS; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; QUESTIONNAIRE; SEX DIFFERENCE; SMOKING CESSATION; SURVIVAL RATE; TREATMENT PLANNING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; HUMANS; IFOSFAMIDE; LUNG NEOPLASMS; MITOMYCIN;

EID: 0035700203     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1013576914283     Document Type: Editorial

References (24)

1. Clinical aspects of chronic obstructive pulmonary disease
2. Recent trends in lung cancer mortality in the United States
3. Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis
4. Activation of ras oncogenes preceding the onset of neoplasia
5. Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung
6. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: A randomised multicentre trial
7. Women and lung cancer: Does oestrogen play a role?
8. Sex-specific expression of gastrin-releasing peptide receptor: Relationship to smoking history and risk of lung cancer
9. The benefits of chemotherapy in patient subgroups with unresectable non-small-cell lung cancer
10. The use of the nitrogen mustards in the palliative treatment of carcinoma. With particular reference to bronchogenic carcinoma
11. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: Effects on survival and quality of life
12. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology
13. The EORTC QLQ-LC13: A modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials
14. Randomized study of paclitaxel-cisplatin vs. cisplain-teniposide in patients with non-small-cell lung cancer
15. Mitomycin, ifosfamide, and cis-platin in non-small-cell lung cancer: Treatment good enough to compare
16. Gemcitabine and cisplatin vs. mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project
17. Do all patients with advanced non-small-cell lung cancer benefit from cisplatin-based combination therapy?
18. Randomized study of vinorelbine and cisplatin vs. vindesine and cisplatin vs. vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients
19. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study
20. Randomized phase III trial of paclitaxel plus carboplatin vs. vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group trial
21. Survival determinants in extensive-stage non-small-cell lung cancer: The Southwest Oncology Group experience
22. Prognostic factors for survival in advanced non-small-cell lung cancer: Univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1052 patients
23. Predictive molecular markers in non-small-cell lung cancer
24. Altered ERCC1 expression correlates with response to cisplatin (DDP) + gemcitabine (Gem) in non-small-cell lung cancer patients (pts)